Clinical Trials Logo

Facial Angiofibromas clinical trials

View clinical trials related to Facial Angiofibromas.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02860494 Withdrawn - Clinical trials for Facial Angiofibromas

Topical Everolimus in Patients With Tuberous Sclerosis Complex

EVEROST
Start date: December 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Tuberous sclerosis complex (TSC) is a rare genetic multisystem disorder characterized by the development of hamartomas in several organs (e.g. brain, heart, kidney, liver, lung), and skin in more than 90% of cases. Facial angiofibromas (FA), present in about 80% of patients, are a stigmatizing hallmark of the disease. Everolimus could be a candidate for use as a topical formulation to treat FA. This adaptive seamless Phase II/III study primary objective is to determine the dose of topical everolimus for treatment of FA and evaluate the efficacy and safety of topical everolimus versus placebo in patients with angiofibromas.